Search research articles
Contact Us
Filters
Showing results (421-430 of 738) with videos related to
Page
of 74
Sort By:
Cancer Medicine
|
September 26, 2024
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, et al.
Gynecologic Oncology
|
June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 14, 2025
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008
S Y Ryu, W Deng, K Albuquerque, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 17, 2015
Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future
Satoru Sagae, Bradley J Monk, Eric Pujade-Lauraine, et al.
JAMIA Open
|
February 7, 2020
A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients
Michael J Pishvaian, Edik M Blais, R Joseph Bender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Josep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.
Gynecologic Oncology
|
September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote, A du Bois, A Floquet, et al.
The Lancet. Oncology
|
April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
The Lancet. Oncology
|
April 12, 2021
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert L Coleman, Domenica Lorusso, Christine Gennigens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
Page
of 74
Search research articles
Search
Showing results (421-430 of 738) with videos related to
Sort By:
Page
of 74
Cancer Medicine
|
September 26, 2024
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, et al.
Gynecologic Oncology
|
June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 14, 2025
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008
S Y Ryu, W Deng, K Albuquerque, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 17, 2015
Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future
Satoru Sagae, Bradley J Monk, Eric Pujade-Lauraine, et al.
JAMIA Open
|
February 7, 2020
A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients
Michael J Pishvaian, Edik M Blais, R Joseph Bender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Josep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.
Gynecologic Oncology
|
September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote, A du Bois, A Floquet, et al.
The Lancet. Oncology
|
April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
The Lancet. Oncology
|
April 12, 2021
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert L Coleman, Domenica Lorusso, Christine Gennigens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
Page
of 74